Sign in
Active, not recruitingNo phase

Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease

Key facts

Who runs it
Assistance Publique Hopitaux De Marseille
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
55 people, planned
Started
24 Jun 2025
Expected to end
24 Aug 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Quantitative neuromuscular MRI
  • Skin biopsy
  • Clinical scores
  • Blood test
  • Patient Report Outcomes Measures
Record updated
28 October 2026

Who can take part

Age
10 years to 30 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Healthy volunteer or patient who has given consent for participation in the study or, for minors, a healthy volunteer whose two parents have given consent for participation in the study
  • Patient with genetically confirmed CMT1A or with a parent whose diagnosis is genetically confirmed
  • Patient able to walk with or without assistance

Who cannot take part

  • Helathy volunteer on long-term therapy
  • Healthy volunteer with neurological disorders
  • Healthy volunteer or patient with a contraindication to MRI,
  • Healthy volunteers or patient under 30 kg
  • Patient with other neuromuscular pathologies
  • Patient in a period of exclusion from another research protocol at the time of signing the consent/non-opposition form
  • Pregnant or breast-feeding women
  • Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (minors, adults under guardianship or trusteeship, patients deprived of their liberty, pregnant or breast-feeding women)
  • Subjects who cannot read and understand the French language well enough to be able to give their consent to participate in research

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a 2-year follow-up study of a cohort of 35 CMT1A patients and 20 healthy volunteers. The main objective is identifying prognostic markers for CMT1A using multi-omics analysis. The study is recruiting subjects between the ages of 10 and 30.

Read full original descriptionShow less

The most common inherited neuropathy is Charcot-Marie-Tooth disease type 1A (CMT1A), caused by a duplication of the gene expressing PMP22. CMT1A patients develop symptoms in early childhood with variable progression and there is no established therapy until now. Therapy must start in childhood, before peripheral nerves degenerate. However, we lack easily obtainable biomarkers in early disease stages.

In CMT-MODs, we will identify disease and prognostic biomarkers in young CMT1A patients.

The 2 groups in the trial

  • Charcot-Marie-Tooth Neuropathy 1AOther group

    Patient with genetically confirmed CMT1A or with a parent whose diagnosis is genetically confirmed,

    Treatment: Quantitative neuromuscular MRI, Skin biopsy, Clinical scores, Blood test, and Patient Report Outcomes Measures

  • Healthy volunteersOther group

    Patient-matched controls

    Treatment: Quantitative neuromuscular MRI, Skin biopsy, Clinical scores, and Blood test

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-omic Approach to the Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease (CMT1A)
Record updated
28 October 2026